Genetic alterations of HER genes in chromophobe renal cell carcinoma

Weng,Wen  Hui; Chen,Ying  Tzu; Yu,Kai  Jie; Chang,Ying  Hsu; Chuang,Cheng  Keng; Pang,See  Tong

doi:10.3892/ol.2016.4198

Genetic alterations of HER genes in chromophobe renal cell carcinoma

Authors:
- Wen Hui Weng
- Ying Tzu Chen
- Kai Jie Yu
- Ying Hsu Chang
- Cheng Keng Chuang
- See Tong Pang
View Affiliations

Affiliations: Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei 10608, Taiwan, R.O.C., Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan, R.O.C.
Published online on: February 8, 2016 https://doi.org/10.3892/ol.2016.4198
Pages: 2111-2116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chromophobe (ch) renal cell carcinoma (RCC) is the 3rd most common subtype of RCC and occurs in 5% of all RCCs. Although chRCC generally demonstrates more favorable outcomes compared with other subtypes of RCC, there is a 6‑7% probability of tumor progression and metastasis in this disease. The subclassification of a more aggressive subtype of chRCC may be useful for the management of this cancer. The Erb‑B2 receptor tyrosine kinase 2 [also known as human epidermal growth factor receptor (HER) 2] gene has been reported to be important in chRCC. The present study aimed to further investigate the abnormalities of the HER family genes and their potential association with chRCC. Fluorescence in situ hybridization was performed on 11 chRCC tissue specimens, and the Spearman’s rank correlation coefficient analysis was used to assess the results. The loss of one copy of the HER2 and HER4 genes was observed to be the major alteration of the tumor cells in all chRCC cases. Statistical data indicated that loss of the HER2 gene was strongly correlated with loss of the HER4 gene (P=0.019). The findings of previous studies were also combined for analysis, and were consistent with those of the present study. In addition, the amplification of HER1 was also strongly correlated with the amplification of HER4 (P=0.004). Furthermore, a high percentage of genetic structural rearrangements was observed in HER3 genes, which was significantly associated with amplification of HER2 (P=0.005). Certain alterations in the HER gene family were also noted as a phenomenom in chRCC. Therefore, the characterization of the underlying aberrant functions of HER genes may be of interest for additional studies in the context of using HER genes to distinguish between RCC subtypes in order to establish improved treatment guidelines.

View Figures

View References

1	Ornellas AA, Andrade DM, Ornellas P, Wisnescky A and Schwindt AB: Prognostic factors in renal cell carcinoma: Analysis of 227 patients treated at the Brazilian National Cancer Institute. Int Braz J Urol. 38:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
2	Vera-Badillo FE, Conde E and Duran I: Chromophobe renal cell carcinoma: A review of an uncommon entity. Int J Urol. 19:894–900. 2012. View Article : Google Scholar : PubMed/NCBI
3	Thoenes W, Störkel S and Rumpelt HJ: Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 48:207–217. 1985. View Article : Google Scholar : PubMed/NCBI
4	Peyromaure M, Misrai V, Thiounn N, Vieillefond A, Zerbib M, Flam TA and Debré B: Chromophobe renal cell carcinoma: Analysis of 61 cases. Cancer. 100:1406–1410. 2004. View Article : Google Scholar : PubMed/NCBI
5	Yusenko MV, Zubakov D and Kovacs G: Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci. 5:517–527. 2009. View Article : Google Scholar : PubMed/NCBI
6	Speicher MR, Schoell B, du Manoir S, Schröck E, Ried T, Cremer T, Störkel S, Kovacs A and Kovacs G: Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 145:356–364. 1994.PubMed/NCBI
7	Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M and Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 22:847–852. 2003. View Article : Google Scholar : PubMed/NCBI
8	Petit A, Castillo M, Santos M, Mellado B, Alcover JB and Mallofré C: KIT expression in chromophobe renal cell carcinoma: Comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol. 28:676–678. 2004. View Article : Google Scholar : PubMed/NCBI
9	Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, et al: Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 10:1962010. View Article : Google Scholar : PubMed/NCBI
10	Weng WH, Ahlén J, Lui WO, Brosjö O, Pang ST, Von Rosen A, Auer G, Larsson O and Larsson C: Gain of 17q in malignant fibrous histiocytoma is associated with a longer disease-free survival and a low risk of developing distant metastasis. Br J Cancer. 79:720–726. 2003. View Article : Google Scholar
11	Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: The HER-2/neu gene and protein. Mol Cell Proteomics. 3:379–398. 2004. View Article : Google Scholar : PubMed/NCBI
12	Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, et al: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 18:1350–1356. 2005. View Article : Google Scholar : PubMed/NCBI
13	Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, et al: Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol. 25:1566–1573. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sergina NV and Moasser MM: The HER family and cancer: Emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 13:527–534. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar : PubMed/NCBI
16	Nahta R and Esteva FJ: HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8:2152006. View Article : Google Scholar : PubMed/NCBI
17	Weidner U, Peter S, Strohmeyer T, Hussnätter R, Ackermann R and Sies H: Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res. 50:4504–4509. 1990.PubMed/NCBI
18	Latif Z, Watters AD, Bartlett JM, Underwood MA and Aitchison M: Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int. 89:5–9. 2002. View Article : Google Scholar : PubMed/NCBI
19	Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B and Henriksson R: ErbB4 is downregulated in renal cell carcinoma - a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol. 43:453–459. 2004. View Article : Google Scholar : PubMed/NCBI
20	Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Störkel S and Kiessling R: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer. 87:349–359. 2000. View Article : Google Scholar : PubMed/NCBI
21	Brunelli M, Delahunt B, Gobbo S, Tardanico R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P, Menestrina F, et al: Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: A validation study combining metaphase and interphase analyses. Am J Clin Pathol. 133:116–126. 2010. View Article : Google Scholar : PubMed/NCBI
22	Iqbal MA, Akhtar M, Ulmer C, Al-Dayel F and Paterson MC: FISH analysis in chromophobe renal-cell carcinoma. Diagn Cytopathol. 22:3–6. 2000. View Article : Google Scholar : PubMed/NCBI
23	Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Cellier D, Azria D, Rouanet P, Senesse P, Ychou M and Lopez-Crapez E: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. Int J Cancer. 128:2938–2946. 2011. View Article : Google Scholar : PubMed/NCBI
24	Yao M, Shuin T, Misaki H and Kubota Y: Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 48:6753–6757. 1988.PubMed/NCBI
25	Moch H, Sauter G, Gasser TC, Bubendorf L, Richter J, Presti JC Jr, Waldman FM and Mihatsch MJ: EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol. 184:424–429. 1998. View Article : Google Scholar : PubMed/NCBI
26	Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, Moskaluk CA and Hewitt SM: Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med. 9:1262011. View Article : Google Scholar : PubMed/NCBI